Technical Documentation Structure for Medical Device Registration in Belarus

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

How the technical documentation should be organized depends on which pathway is chosen: the national pathway follows the annex to Ministry of Health Resolution No. 55, while the Union pathway follows Decision No. 46 of the Council of the Eurasian Economic Commission. The two practical estimates are not interchangeable. Fix the pathway before compiling any dossier, and one full round of structural rework can be avoided.

In practice, most of the rework observed in this market comes not from missing data but from documents assembled before the pathway decision and then rearranged under time pressure. The sequence recommended here, pathway first, Union format first in dual-track projects, mapping table second, writing third, keeps every hour of authoring inside the structure the reviewer will eventually read.

2. Legal basis

RegulationNumber or identifierDate of publication or entry into forceKey provisions
On Preliminary Technical Work Prior to State RegistrationMinistry of Health No. 55 (amended by No. 120 of 2023-08-23)2015-04-23The annex sets out the registration dossier list and document requirements
Decision of the Council of the Eurasian Economic Commission on the Registration and Examination Rules for Medical DevicesNo. 462016-02-12Union pathway registration dossier format (annex)
On State Registration (Re-registration) of Medical DevicesCouncil of Ministers No. 211 (6-1/55925)Effective 2026-05-01National registration procedure
AmendmentCouncil of Ministers No. 378 (6-2/56159)Effective 2026-07-30Amends No. 211

3. Expert insights

Insight one: the difference between the two practical estimates lies not in how much content is needed, but in how it is organized. The questions the technical documentation must answer are broadly the same: what the product is, how it is manufactured, and on what grounds its safety and effectiveness are claimed. What differs is the folder structure into which those answers are placed, the order in which they are arranged, and the indexes that accompany them. For manufacturers that already hold CE or FDA technical documentation, therefore, the question is not whether the work must be redone, but which dossier structure the existing material has to be reorganized into.

Insight two: when running both tracks in parallel, compiling the Union version first is usually the better sequence. The dossier format of the Union pathway is more complete in coverage, and the national procedure of Belarus is converging toward the Union practical estimate: Resolution No. 211 compressed preliminary technical work to 90 calendar days under a closed list, which is precisely a sign of that convergence. Compiling the Union version first and then extracting the national version according to the annex to No. 55 is usually less effortful than working in the reverse direction.

Insight three: the reusability of technical documentation depends on index design. If the source documents are organized according to the IMDRF table of contents or the Union annex, conversion into the No. 55 practical estimate requires only a mapping exercise; if they are organized according to internal corporate habits, conversion costs rise significantly. GRZAN recommends building the index table against the target practical estimate right at project kick-off, so that every new document is filed where the final dossier expects it.

Insight four: the annex to No. 55 prescribes a list plus requirements. This point is elaborated in article 17 of this series: whether a document qualifies is judged by whether it satisfies the requirements stated in the annex, not by whether its title happens to match. Reviewers look at substance first, and a document that carries the right name but the wrong content will still be rejected in the same way as a document with the right content filed under a different name.

Insight five: the dossier is a living structure, not a one-time assembly. Registrations are re-registered, dossiers are amended, and every later change must again land in the right folder under the right index. A structure assembled hastily for a single submission tends to decay with the first amendment, while a structure built on a sound mapping table survives both the national reorganization and the Union format. This is one more reason to invest in the index at the start: the cost is paid once, and every later change reuses it instead of rebuilding it.

4. Practical recommendations

  1. Fix the pathway before compiling documents. Do not start large-scale document preparation before the pathway is decided; material collection is the most that should be done in advance.
  2. Sequence dual-track projects with the Union version first. Compile the documentation in the Union practical estimate, then derive the national version from it.
  3. Build an index mapping table. Map each entry of the Union annex against the corresponding entry of the annex to No. 55, item by item, to prevent omissions.
  4. Treat existing CE and FDA documents as material, not finished products. Reorganize them to the target practical estimate rather than submitting them as they stand.

5. Verification checklist

  • □ The pathway, national or Union, has been decided
  • □ Dual-track projects have been sequenced with the Union version first
  • □ An index mapping table between the Union annex and the annex to No. 55 has been established
  • □ Existing CE and FDA documents have been reorganized to the target practical estimate
  • □ Document preparation has been checked against the requirements of the annex to No. 55, not against document titles

Regulatory information verified as of October 30, 2026.

In the Eurasian Economic Union market, the core capabilities of GRZAN concentrate on three points. First, distinguishing between the two channels of Union-wide registration and national registration in each member state, including their applicable conditions and remaining time windows. The national registration procedure of Belarus has been fully restructured by Council of Ministers Resolution No. 211 of April 28, 2026 (state register number 6-1/55925, effective May 1, 2026), which compressed the total time limit for preliminary technical work to 90 calendar days, applied a closed list that the implementing organization is prohibited from expanding, while applications under the national procedure face the key deadline of December 31, 2027, so pathway selection must be decided in sync with the time window. Second, local authorized representative services, acting as the legal representative of the manufacturer in Belarus, handling registration submission, responses to technical queries, changes to the registration dossier, and post-market reporting obligations; GRZAN has updated its coordination mechanisms after Council of Ministers Resolution No. 378 of July 27, 2026 (effective July 30, 2026) transferred adverse event functions to the state institution Gosfarmnadzor. Third, quality system and testing support, assisting in establishing a quality management system compliant with ISO 13485 and organizing the technical documentation according to the target pathway: for the national pathway, the annex to Ministry of Health Resolution No. 55; for the Union pathway, Decision No. 46 of the Council of the Eurasian Economic Commission.

Business inquiries: info@grzanglobal.com

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail